Cardiometabolic risk factors, and the chronic cardiovascular diseases (CVDs) that result from them, are highly prevalent in the US and amenable to clinical nutrition interventions. This creates an urgency to develop comprehensive care models that incorporate prevention-based actions by improving lifestyle routines. Such care models should account for social determinants of health, ethnocultural variables, and challenges to sustainability. The relevance of these newly designed chronic care models is to inform and facilitate early intervention, primarily consisting of lifestyle changes and healthy nutrition, which mitigates progression from one stage to subsequent, higher morbidity stages to a greater extent than late intervention. In this article, the mechanistic drivers and ethnocultural validation of the Cardiometabolic-Based Chronic Disease (CMBCD) model are reviewed. Main findings are that in CMBCD, primary (genetics, environment, and behavior) and metabolic (obesity as Adiposity-Based Chronic Disease [ABCD], type 2 diabetes as Dysglycemia-Based Chronic Disease [DBCD], hypertension, and dyslipidemia) drivers initiate and perpetuate the progression of CVD. Epidemiological findings and molecular mechanisms support intra-ABCD/DBCD, as well as ABCD to DBCD stage progression culminating in CVD. The ABCD definition overcomes weight stigma and body mass index underperformance by considering adiposity amount, distribution, and function; and the DBCD definition overcomes criticisms of prediabetes and an exclusive glucocentric approach by considering insulin resistance and residual vascular risk along a clinical spectrum. In conclusion, clinicians should approach patients using the CMBCD model to incorporate lifestyle changes as early as possible to optimally mitigate the burden of CVD.

Department of Global Health and Population Harvard T H Chan School of Public Health Harvard University Boston Massachusetts USA

Division of Endocrinology Diabetes and Bone Disease Icahn School of Medicine at Mount Sinai New York New York USA

Foundation for Clinic Public Health and Epidemiological Research of Venezuela Caracas Venezuela

International Clinical Research Center Brno Czech Republic

LifeDoc Health Memphis Tennessee USA

The Marie Josée and Henry R Kravis Center for Cardiovascular Health at Mount Sinai Heart Icahn School of Medicine at Mount Sinai New York New York USA

Zobrazit více v PubMed

NCD-RisC. Trends in cardiometabolic risk factors in the Americas between 1980 and 2014: a pooled analysis of population-based surveys. Lancet Glob Health. 2020;8(1):e123-e133.

Sperling LS, Mechanick JI, Neeland IJ, et al. The Cardiometabolic health alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 2015;66(9):1050-1067.

Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2010;53(4):600-605.

Ueda P, Woodward M, Lu Y, et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol. 2017;5(3):196-213.

Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of Risk Assessment Tools to Guide Decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American heart association and American college of cardiology. Circulation. 2019;139(25):e1162-e1177.

Mechanick J, Garber AJ, Handelsman Y, Garvey WT. AACE position statement. American association of clinical endocrinologists position statement on obesity and obesity medicine. Endocr Pract. 2012;18(5):642-648.

Mechanick JI, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: the American association of clinical endocrinologists and American college of endocrinology position statement. Endocr Pract. 2017;23(3):372-378.

Mechanick JI, Garber AJ, Grunberger G, Handelsman Y, Garvey WT. Dysglycemia-based chronic disease: an American Association of Clinical Endocrinologists Position Statement. Endocr Pract. 2018;24(11):995-1011.

Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(5):525-538.

Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(5):539-555.

Mechanick JI, Rosenson RS, Pinney SP, Mancini DM, Narula J, Fuster V. Coronavirus and cardiometabolic syndrome: JACC focus seminar. J Am Coll Cardiol. 2020;76(17):2024-2035.

Alberts CJ, Dorofee AJ. A Framework for Categorizing Key Drivers of Risk. Software Engineering Institute; 2009. Technical report no. CMU/SEI-2009-TR-007 ESC-TR-2009-007. Accessed March 20, 2021. https://resources.sei.cmu.edu/library/asset-view.cfm?assetid=9093

Banack HR, Stokes A. The ‘obesity paradox’ may not be a paradox at all. Intl J Obes. 2017;41(8):1162-1163.

Elagizi A, Kachur S, Lavie CJ, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2018;61(2):142-150.

Cardiometabolic abnormalities among normal-weight persons from five racial/ethnic groups in the United States: a cross-sectional analysis of two cohort studies. Ann Intern Med 2017;166(9):628-636.

Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935-2959.

Nieto-Martinez R, Gonzalez-Rivas JP, Aschner P, Barengo NC, Mechanick JI. Transculturalizing diabetes prevention in Latin America. Ann Glob Health. 2017;83(3-4):432-443.

Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes. 2008;32(6):959-966.

Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.

Nieto-Martínez R, González-Rivas JP, Ugel E, et al. Application of the AACE/ACE advanced framework for the diagnosis of obesity and cardiometabolic disease staging in a general population from 3 regions of Venezuela: the VEMSOLS Study Results. Endocr Pract. 2018;24(1):6-13.

Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485-497.

Wu YK, Berry DC. Impact of weight stigma on physiological and psychological health outcomes for overweight and obese adults: a systematic review. J Adv Nurs. 2018;74(5):1030-1042.

Papadopoulos S, Brennan L. Correlates of weight stigma in adults with overweight and obesity: a systematic literature review. Obesity (Silver Spring). 2015;23(9):1743-1760.

Jackson SE, Steptoe A, Beeken RJ, Croker H, Wardle J. Perceived weight discrimination in England: a population-based study of adults aged -50 years. Int J Obes (Lond). 2015;39(5):858-864.

Vartanian LR, Porter AM. Weight stigma and eating behavior: a review of the literature. Appetite. 2016;102:3-14.

Nieto-Martínez R, González-Rivas JP, Medina-Inojosa JR, Florez H. Are eating disorders risk factors for Type 2 Diabetes? A systematic review and meta-analysis. Curr Diab Rep. 2017;17(12):138.

Schvey NA, Puhl RM, Brownell KD. The impact of weight stigma on caloric consumption. Obesity (Silver Spring). 2011;19(10):1957-1962.

Han S, Agostini G, Brewis AA, Wutich A. Avoiding exercise mediates the effects of internalized and experienced weight stigma on physical activity in the years following bariatric surgery. BMC Obes. 2018;5:18.

Sattler KM, Deane FP, Tapsell L, Kelly PJ. Gender differences in the relationship of weight-based stigmatisation with motivation to exercise and physical activity in overweight individuals. Health Psychol Open. 2018;5(1):2055102918759691.

Jackson SE, Steptoe A. Association between perceived weight discrimination and physical activity: a population-based study among English middle-aged and older adults. BMJ Open. 2017;7(3):e014592.

Frühbeck G, Busetto L, Dicker D, et al. The ABCD of Obesity: an EASO position statement on a diagnostic term with clinical and scientific implications. Obes Facts. 2019;12(2):131-136.

Garvey WT, Mechanick JI. Proposal for a scientifically correct and medically actionable disease classification system (ICD) for obesity. Obesity (Silver Spring). 2020;28(3):484-492.

Lee JJ, Pedley A, Hoffmann U, Massaro JM, Levy D, Long MT. Visceral and intrahepatic fat are associated with cardiometabolic risk factors above other ectopic fat depots: the Framingham heart study. Am J Med. 2018;131(6):684-692. e612.

Chang L, Garcia-Barrio MT, Chen YE. Perivascular adipose tissue regulates vascular function by targeting vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2020;40(5):1094-1109.

Guenther M, James R, Marks J, Zhao S, Szabo A, Kidambi S. Adiposity distribution influences circulating adiponectin levels. Transl Res. 2014;164(4):270-277.

Salazar J, Luzardo E, Mejías JC, Rojas J. Epicardial fat: physiological, pathological, and therapeutic implications. Cardiol Res Pract. 2016;2016:1291537.

Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia. 2008;51(10):1781-1789.

Mende CW, Einhorn D. Fatty kidney disease: a new renal and endocrine clinical entity? describing the role of the kidney on obesity, metabolic syndrome, and Type 2 diabetes. Endocr Pract. 2019;25(8):854-858.

Kremer R, GilsanzV. Fat and bone: an odd couple. Front Endocrinol (Lausanne). 2015;6:190.

Hamrick MW, McGee-Lawrence ME, Frechette DM. Fatty infiltration of skeletal muscle: mechanisms and comparisons with bone marrow adiposity. Front Endocrinol (Lausanne). 2016;7:69.

Ying W, Lee YS, Dong Y, et al. Expansion of islet-resident macrophages leads to inflammation affecting β cell proliferation and function in obesity. Cell Metabolism. 2019;29(2):457-474. e455.

Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363(23):2211-2219.

Boggs DA, Rosenberg L, Cozier YC, et al. General and abdominal obesity and risk of death among black women. N Engl J Med. 2011;365(10):901-908.

Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews. 2017;18(7):715-723.

Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer - Viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794-798.

Yudkin JS, Montori VM. The epidemic of pre-diabetes: the medicine and the politics. BMJ. 2014;349:g4485.

Cefalu WT, Petersen MP, Ratner RE. The alarming and rising costs of diabetes and prediabetes: a call for action!. Diabetes Care. 2014;37(12):3137-3138.

Ligthart S, van Herpt TT, Leening MJ, et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4(1):44-51.

Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753-759.

Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Physical Therapy. 2008;88(11):1322-1335.

Ali MK, Bullard KM, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014. Lancet Diabetes Endocrinol. 2018;6(5):392-403.

Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953.

Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279-2290.

Group Diabetes Prevention Program Research. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.

Tabak RG, Sinclair KA, Baumann AA, et al. A review of diabetes prevention program translations: use of cultural adaptation and implementation research. Transl Behav Med. 2015;5(4):401-414.

Nazimek-Siewniak B, Moczulski D, Grzeszczak W. Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design. J Diabetes Complications. 2002;16(4):271-276.

Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-551.

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.

Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020;(360):1-8.

Ogden CL, Carroll MD. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-1555.

National Center for Health Statistics (NCHS) fact sheet. National Health and Nutrition Examination Survey. July 2020. Accessed March 28, 2021. https://www.cdc.gov/nchs/data/factsheets/factsheet_nhanes.pdf.

Martins C, Godycki-Cwirko M, Heleno B, Brodersen J. Quaternary prevention: reviewing the concept. Eur J Gen Pract. 2018;24(1):106-111.

Nieto-Martinez R, Gonzalez-Rivas JP, Florez H, Mechanick JI. Transcultural endocrinology: adapting Type-2 Diabetes Guidelines on a Global Scale. Endocrinol Metab Clin North Am. 2016;45(4):967-1009.

Rao G, Powell-Wiley TM, Ancheta I, et al. Identification of obesity and cardiovascular risk in ethnically and racially diverse populations. Circulation. 2015;132(5):457-472.

Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic. Int J Epidemiol. 2020;49(3):810-823.

Taylor HA Jr, Coady SA, Levy D, et al. Relationships of BMI to cardiovascular risk factors differ by ethnicity. Obesity (Silver Spring). 2010;18(8):1638-1645.

Nieto-Martinez R, Gonzalez-Rivas J. Transcultural lifestyle medicine. In: Mechanick JI, Kushner RF, eds. Creating a Lifestyle Medicine Center: From Concept to Clinical Practice. New York: Springer; 2020:233-248.

Warter L, Warter I. The challenge of cultural differences in diabetes prevention. In: Proceedings of The XIIIth National Conference on Bioethics With International Participation. Bologna: Filodirtto; 2019:87-93.

Gonzalez-Rivas JP, Mechanick JI, Hernandez JP, et al. Prevalence of adiposity-based chronic disease in middle-aged adults from Czech Republic. The Kardiovize Study. Obes Sci Pract. 2021;27(5):455-462.

Gonzalez-Rivas JP, Mechanick JI, Infante-Garcia MM, et al. The prevalence of dysglycemia-based chronic disease in a European population - a new paradigm to address diabetes burden: a Kardiovize study. Endocr Pract. 2021;27(5):455-462.

Telehealth and cardiometabolic-based chronic disease: optimizing preventive care in forcibly displaced migrant populations

Lifestyle Medicine in Diabetes Care: The Lifedoc Health Model